10-Q/A: CIMG Q2 2025 10-Q/A: Zero sales, cash strain

CIMG reported no revenue for the quarter, minimal cash, heavy inventory build, and highlighted Nasdaq delisting risk while converting $10M of notes to equity and cutting operating costs.

Summary

• Quarter ended March 31, 2025: revenue $0 (vs $323,406 prior-year quarter); net loss $385,556 (vs $1,653,931).
• Six months ended March 31, 2025: revenue $22,853 (vs $1,289,338); net loss $1,921,805 (vs $3,802,542).
• Cash at March 31, 2025 was $2,404; operating cash outflow for the six months was $10,294,334.
• Inventory rose to $12,751,596 (mostly raw materials $12,627,194), up from $4,548,035 at September 30, 2024.
• Current liabilities fell to $2,480,889 (from $6,238,323), aided by the conversion of debt; total liabilities $2,480,889.
• Stockholders’ equity improved to $10,621,422 from $(650,668), reflecting conversions and equity issuances.
• Shares outstanding: 30,197,418 at March 31, 2025; 188,180,751 as of September 17, 2025.
• Converted $10,000,000 of 7% convertible notes into 19,457,618 shares on March 18, 2025; issued 25,641,023 new warrants at $0.39 exercise (expiring Jan 2027).
• Nasdaq listing risk: received delisting determination on June 27, 2025 for late FY2024 10-K; intends to appeal and file by July 7, 2025.
• Internal control over financial reporting assessed as not effective as of March 31, 2025.
• Completed PRC acquisitions: Beijing Xilin (51%) on March 31, 2025; Shanghai Huomao (51%) on April 22, 2025 (Huomao consideration: 200,000 common shares, six-month lock-up).

Sentiment

Score: 3

Explanation: Severe revenue decline, minimal cash, significant cash burn, delisting risk, and control weaknesses outweigh positives from cost reductions, liability conversions, and strategic acquisitions.

Positives

• Net loss narrowed year-over-year: Q2 loss $385,556 (down 76.7%); six-month loss $1,921,805 (down 49.5%).
• Operating expenses reduced: down 40.6% in Q2 to $752,677; down 33.5% to $2,270,435 for six months.
• Balance sheet de-risking: convertible notes eliminated by conversion; current liabilities reduced to $2,480,889 (from $6,238,323).
• Equity position improved to $10,621,422 from $(650,668) at September 30, 2024.
• New capital accessed: $2,000,000 private placement and $9,561,299 ATM issuance during the six months; additional private placement $1,068,480 closed June 9, 2025.
• Other income improved ($403,635 six months) mainly from settlement/forgiveness of accounts payable.
• Strategic expansion into Asia advanced via acquisitions of Beijing Xilin (51%) and Shanghai Huomao (51%).

Negatives

• Revenue collapse: $0 in Q2 and only $22,853 for six months (down 98.2% year-over-year).
• Cash critically low at $2,404 with substantial operating cash burn of $10,294,334 in six months.
• Large inventory build to $12,751,596 ties up working capital and heightens execution risk of sell-through.
• Going concern uncertainty disclosed; management expects to need immediate additional capital.
• Nasdaq delisting determination for late FY2024 10-K filing; trading suspension risk without successful appeal.
• Internal control over financial reporting not effective as of March 31, 2025.
• Ongoing litigation (Kim case seeking $1,041,216; ex-directors seeking >$200,000) with potential adverse outcomes.
• Subscription receivable of $438,701 recorded, reducing quality of equity raised.

Risks

• Ability to continue as a going concern and need to obtain additional funding immediately to support operations.
• Nasdaq listing compliance risk, including a June 27, 2025 delisting determination related to a late 10-K filing.
• Reliance on third-party roasters and manufacturing partners to produce products and fulfill co-packing services.
• Competitive pressures in functional beverages and co-packing services that could impact margins and growth.
• Regulatory developments in the U.S. and non-U.S. markets that may affect operations.
• Retention of key management, sales and marketing personnel.
• Protection and maintenance of intellectual property rights.
• Internal control over financial reporting not effective as of March 31, 2025.
• Ongoing litigation (Kim litigation; ex-directors lawsuit) with uncertain outcomes.
• Customer concentration risk (e.g., Customer LXM represented 59% of H1 FY2025 revenue).

Future Outlook

Management expects revenue to improve in subsequent quarters as new sales channels for the Maca functional beverage line mature, but plans to raise additional capital immediately to fund operations and intends to appeal the Nasdaq delisting determination while working to regain compliance.

Management Comments

• Does not expect the six months ended March 31, 2025 revenue to predict future quarters, given the focus on expanding channels for the Maca series.
• Anticipates the need to raise additional capital immediately to continue funding operations and execute strategy.
• Intends to appeal the Nasdaq delisting determination and file the FY2024 Form 10-K by the appeal deadline.
• Operating expense reductions reflect lower warehousing, labor, and professional service costs.

Industry Context

The pivot from specialty coffee and co-packing toward functional beverages aligns with broader consumer trends in Asia for health-oriented products. However, unlike scaled peers with strong distribution (e.g., established functional drink producers), microcap entrants face higher funding and execution risks, especially when supply chains and third-party manufacturing are critical.

Comparison to Industry Standards

• Liquidity: Cash of $2,404 and heavy operating cash burn are well below norms for established beverage peers (e.g., Celsius, Monster) that maintain robust liquidity; this profile is more typical of microcap developmental-stage companies.
• Growth and revenue scale: Reporting $0 quarterly revenue contrasts with rapid growth peers in functional beverages; execution risk remains until distribution and sell-through materialize.
• Gross margin: The reported six-month gross margin of 67.7% on a small base is directionally consistent with premium beverage margins, but sustainability depends on scaling volumes.
• Governance and controls: Internal controls deemed not effective, a weakness versus larger public beverage and CPG peers that typically maintain effective SOX controls.
• Listing compliance: Nasdaq delisting risk due to late filings is a notable deviation from industry best practices among listed consumer companies.

Legal Proceedings

• Curtin litigation: Settled November 8, 2024 for $125,000; case dismissed January 22, 2025.
• Kim litigation: Filed October 3, 2024 seeking $1,041,216; preliminary injunction denied February 13, 2025; discovery ongoing.
• Ex-Directors lawsuit: Filed March 10, 2025 seeking >$200,000 for unpaid fees/expenses; request for entry of default filed April 17, 2025; parties negotiating.

Related Party Transactions

• Directors of Wewin Technology LLC paid an administrative fee of $28,500 on behalf of CIMG Inc.; amount outstanding as of March 31, 2025 with expectation to repay by September 30, 2025.
• Convertible Note-related party of $319,220 outstanding at September 30, 2024 was eliminated by March 31, 2025.

Stakeholder Impact

• Shareholders: Significant dilution from note conversions and equity issuances; potential share price impact from delisting risk.
• Employees: Going concern uncertainty and funding needs may affect job security and growth initiatives.
• Customers and distributors: Strategy pivot and channel build-out may delay product availability and scale-up.
• Suppliers: Large inventory purchases suggest future demand expectations; payment timing dependent on capital availability.
• Creditors: Short-term loans outstanding; liquidity constraints heighten counterparty risk.
• Warrant holders: Potential upside if warrants are exercised and company executes growth plan.

Next Steps

• Appeal the Nasdaq delisting determination and file the FY2024 Form 10-K by the stated deadline.
• Raise additional capital immediately to support ongoing operations and execution of the Asian market strategy.
• Integrate Beijing Xilin and Shanghai Huomao and convert large raw material inventories into sell-through.
• Expand distribution channels for the Maca series across online and offline points of sale.
• Resolve ongoing litigation (Kim litigation and ex-directors lawsuit) to reduce uncertainty.
• Address internal control deficiencies over financial reporting.

Key Dates

Recommendation

The combination of zero quarterly revenue, critical cash levels, heavy operating cash burn, Nasdaq delisting risk, internal control weaknesses, and ongoing litigation presents a high-risk profile. While liabilities were reduced via conversions and the strategy includes acquisitions and cost cuts, near-term funding and execution risks dominate.

Keywords

CIMG, IMG, 10-Q/A, going concern, Nasdaq delisting, convertible notes, warrants, private placement, functional beverages, Maca series, Beijing Xilin, Shanghai Huomao, inventory, cash burn, Asia expansion, Regulation S, equity issuance, internal controls